June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
April 26, 2023
WFMZ-TV in Allentown, Pennsylvania highlighted the University of Cincinnati's John Byrd and the Beat AML study testing personalized treatment for patients with acute myelogenous leukemia.
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.
November 7, 2023
The University of Cincinnati Cancer Center’s Vladimir Bogdanov found a new drug developed in his lab was effective at preventing pancreatic cancer growth and spread when combined with chemotherapy in lab tests.
December 8, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology Annual Meeting, held Dec. 9-12 in San Diego, California.
February 15, 2024
The University of Cincinnati Cancer Center announced it is opening the Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, this summer.
February 20, 2024
The University of Cincinnati Cancer Center is the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
April 4, 2024
Clinical research conducted at the University of Cincinnati College of Medicine and UC Health played a role in the U.S. Food and Drug Administration's March 26 approval of WINREVAIR™ (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH) in adults.
November 2, 2022
A collaborative research team at the University of Cincinnati has received a $3.5 million National Institutes of Health grant to examine how current HIV medications are affected by alcohol use alone or in combination with fentanyl.
August 10, 2022
University of Cincinnati researchers Jason Gardner and Matthew Robson are studying whether targeting an inflammation pathway that affects burns and traumatic brain injuries can be an effective treatment for both conditions.